title: Angiotensin II produces nociceptive behavior through spinal AT1 receptor-mediated p38 mitogen-activated protein kinase activation in mice.
abstract: BACKGROUND
  It has been demonstrated that angiotensin II (Ang II) participates in either the inhibition or the facilitation of nociceptive transmission depending on the brain area. Neuronal Ang II is locally synthesized not only in the brain, but also in the spinal cord. Though the spinal cord is an important area for the modulation of nociception, the role of spinal Ang II in nociceptive transmission remains unclear. Therefore, in order to elucidate the role of Ang II in nociceptive transmission in the spinal cord, we examined the effect of intrathecal (i.t.) administration of Ang II into mice.
  
  
  RESULTS
  I.t. administration of Ang II produced a behavioral response in mice mainly consisting of biting and/or licking of the hindpaw and the tail along with slight hindlimb scratching directed toward the flank. The behavior induced by Ang II (3 pmol) was dose-dependently inhibited by intraperitoneal injection of morphine (0.1-0.3 mg/kg), suggesting that the behavioral response is related to nociception. The nociceptive behavior was also inhibited dose-dependently by i.t. co-administration of losartan (0.3-3 nmol), an Ang II type 1 (AT1) receptor antagonist, and SB203580 (0.1-1 nmol), a p38 MAPK inhibitor. However, the Ang II type 2 (AT2) receptor antagonist PD123319, the upstream inhibitor of ERK1/2 phosphorylation U0126, and the JNK inhibitor SP600125 had no effect on Ang II-induced nociceptive behavior. Western blot analysis showed that the i.t. injection of Ang II induced phosphorylation of p38 MAPK in the lumbar dorsal spinal cord, which was inhibited by losartan, without affecting ERK1/2 and JNK. Furthermore, we found that AT1 receptor expression was relatively high in the lumbar superficial dorsal horn.
  
  
  CONCLUSIONS
  Our data show that i.t. administration of Ang II induces nociceptive behavior accompanied by the activation of p38 MAPK signaling mediated through AT1 receptors. This observation indicates that Ang II may act as a neurotransmitter and/or neuromodulator in the spinal transmission of nociceptive information.
authors.forename: Wataru
authors.initials: W
authors.lastname: Nemoto
authors.forename: Osamu
authors.initials: O
authors.lastname: Nakagawasai
authors.forename: Fukie
authors.initials: F
authors.lastname: Yaoita
authors.forename: Syu-Ichi
authors.initials: S
authors.lastname: Kanno
authors.forename: Shin
authors.initials: S
authors.lastname: Yomogida
authors.forename: Masaaki
authors.initials: M
authors.lastname: Ishikawa
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tadano
authors.forename: Koichi
authors.initials: K
authors.lastname: Tan-No
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D007093:Imidazoles / Q000378:metabolism / Q000494:pharmacology; D019808:Losartan; D020935:MAP Kinase Signaling System / Q000187:drug effects; D008297:Male; D051379:Mice; D011725:Pyridines / Q000378:metabolism / Q000494:pharmacology; D044140:Receptor, Angiotensin, Type 1 / Q000378:metabolism*; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D007093:Imidazoles; D011725:Pyridines; D044140:Receptor, Angiotensin, Type 1; D000804:Angiotensin II; C073402:PD 123319; D048051:p38 Mitogen-Activated Protein Kinases; D019808:Losartan; C093642:SB 203580
references.citation: Pharmacol Rev. 1993 Jun;45(2):205-51
references.pmid: 8372104
references.citation: Neuroreport. 2002 Dec 20;13(18):2483-6
references.pmid: 12499853
references.citation: Hypertension. 2000 Oct;36(4):549-52
references.pmid: 11040234
references.citation: Prog Neurobiol. 2011 Sep 15;95(1):49-67
references.pmid: 21777652
references.citation: J Neurosci. 2003 May 15;23(10):4017-22
references.pmid: 12764087
references.citation: Regul Pept. 2001 Jun 15;99(2-3):93-101
references.pmid: 11384770
references.citation: Pharmacol Biochem Behav. 1999 Feb;62(2):229-32
references.pmid: 9972688
references.citation: PLoS Med. 2006 Sep;3(9):e338
references.pmid: 16953659
references.citation: Mol Cell Endocrinol. 2009 Apr 29;302(2):111-7
references.pmid: 19418627
references.citation: J Neurochem. 2005 Aug;94(3):742-52
references.pmid: 16033422
references.citation: J Biol Chem. 1998 Jan 16;273(3):1741-8
references.pmid: 9430721
references.citation: Physiol Rev. 2006 Jul;86(3):747-803
references.pmid: 16816138
references.citation: Pain. 2002 Sep;99(1-2):175-84
references.pmid: 12237195
references.citation: Pain. 2005 Jan;113(1-2):51-60
references.pmid: 15621364
references.citation: Pain. 2005 Feb;113(3):301-309
references.pmid: 15661437
references.citation: Pain. 2004 Oct;111(3):278-285
references.pmid: 15363871
references.citation: J Neurosci. 2002 Sep 1;22(17):7737-45
references.pmid: 12196597
references.citation: Mol Pain. 2008 Apr 30;4:17
references.pmid: 18445299
references.citation: Brain Res Rev. 2009 Apr;60(1):135-48
references.pmid: 19150373
references.citation: Circ Res. 2005 Oct 14;97(8):772-80
references.pmid: 16151022
references.citation: Regul Pept. 2010 Jun 8;162(1-3):90-8
references.pmid: 20346377
references.citation: Nat Neurosci. 1999 Dec;2(12):1114-9
references.pmid: 10570489
references.citation: Neuroscience. 2009 Feb 18;158(4):1301-10
references.pmid: 19116162
references.citation: Behav Brain Res. 2003 Jun 16;142(1-2):63-7
references.pmid: 12798266
references.citation: J Neurochem. 2003 Sep;86(6):1534-44
references.pmid: 12950462
references.citation: Neuropeptides. 2007 Feb;41(1):33-8
references.pmid: 17140659
references.citation: J Endocrinol. 2008 Apr;197(1):85-93
references.pmid: 18372235
references.citation: Adv Exp Med Biol. 2010;690:89-105
references.pmid: 20700839
references.citation: Neurosci Lett. 2008 Jan 31;431(2):129-34
references.pmid: 18191894
references.citation: Anesth Analg. 2007 Dec;105(6):1838-44, table of contents
references.pmid: 18042890
references.citation: Exp Cell Res. 2012 Oct 1;318(16):2105-15
references.pmid: 22749815
references.citation: Neuroscience. 2008 Jun 2;153(4):1245-55
references.pmid: 18440713
references.citation: Neuroreport. 2003 Jun 11;14(8):1153-7
references.pmid: 12821799
references.citation: Annu Rev Pharmacol Toxicol. 2010;50:439-65
references.pmid: 20055710
references.citation: Neuroscience. 2009 Dec 15;164(3):1263-73
references.pmid: 19747525
references.citation: Brain Res. 2008 Dec 30;1246:111-22
references.pmid: 18976642
references.citation: J Pharmacol Sci. 2007 May;104(1):39-45
references.pmid: 17452810
references.citation: Brain Res. 2002 Oct 11;952(1):7-14
references.pmid: 12363399
references.citation: Neurosci Biobehav Rev. 2004 Jan;27(8):729-37
references.pmid: 15019423
references.citation: Brain Res Mol Brain Res. 2003 Aug 19;116(1-2):126-34
references.pmid: 12941468
references.citation: Brain Res. 2003 May 16;972(1-2):207-15
references.pmid: 12711094
references.citation: Neuroscience. 2005;132(2):453-63
references.pmid: 15802196
references.citation: Circulation. 1993 Dec;88(6):2849-61
references.pmid: 8252698
references.citation: Peptides. 2011 Oct;32(10):2141-50
references.pmid: 21945916
references.citation: Peptides. 1999;20(3):335-42
references.pmid: 10447091
references.citation: Pharmacol Rev. 2000 Sep;52(3):415-72
references.pmid: 10977869
references.citation: Eur J Pharmacol. 1980 Oct 17;67(2-3):313-6
references.pmid: 6893963
references.citation: Pain. 2000 May;86(1-2):55-61
references.pmid: 10779660
references.citation: Neurosci Lett. 1993 Sep 3;159(1-2):9-12
references.pmid: 8264986
references.citation: Life Sci. 1996;59(21):PL331-6
references.pmid: 8937511
references.citation: Peptides. 2011 Jul;32(7):1551-65
references.pmid: 21699940
references.citation: Mol Immunol. 2012 May;51(1):51-6
references.pmid: 22387269
references.citation: Glia. 2004 Jan 1;45(1):89-95
references.pmid: 14648549